Drug Profile
VNP 20009
Latest Information Update: 14 Oct 2002
Price :
$50
*
At a glance
- Originator Vion Pharmaceuticals
- Developer EPTTCO; Vion Pharmaceuticals
- Class Antineoplastics; Gene therapies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Lymphoma; Solid tumours
Most Recent Events
- 14 Oct 2002 Discontinued - Phase-I for Cancer in USA (IV-injection)
- 14 Oct 2002 Discontinued - Phase-I for Lymphoma in England (IV)
- 14 Oct 2002 Discontinued - Phase-I for Solid tumours in United Kingdom (IV-injection)